€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?

Europe’s biotech ecosystem just notched a headline-grabbing win. Azafaros, a Netherlands-based rare-disease upstart, secured an oversubscribed €132 million Series B funding to propel its lead neurology drug into parallel phase 3 trials. The sheer size of this raise – roughly $147 million – is turning heads on both sides of the Atlantic. It’s not just a big number for Europe; it’s a statement. After years trailing U.S. biotech in scale and speed, Europe may be quietly repositioning itself as a hub for neurological and rare disease innovation. Is the continent, long seen as a junior partner in biotech, poised to become the new “neurology capital” of the world?

 » Read More